Multiple Analysts Initiate Coverage of Immuron with Double-Digit Price Targets

Oct. 31, 2017 |  More About Immuron


Immuron (ASX: IMC and NASDAQ: IMRN) has caught Wall Street’s attention in recent months.

The Australian-biotech, which began trading on the NASDAQ over the summer, received research coverage from analysts at Joseph Gunnar in September HC Wainwright in October.

The leading small-cap firms have both put a price target of $15 per share on Immuron, representing 200% upside from the recent trading range.

In their reports (available here), the analysts note the potential of the Company’s multiple immunotherapy development programs which are targeting large markets.

One of its clinical-stage candidates, IMM-529, is targeting Clostridium difficile-related infections (CDI), a hospital-acquired or non-socomial infection associated with multi-drug resistance. Initial enrollment for this potential blockbuster program is expected in the near-term.

Immuron also has multiple Phase 2 trials underway for its IMM-124E candidate, which targets liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Additional pre-clinical work is underway targeting central nervous system (CNS) diseases and neuropsychiatric conditions, such as autism spectrum disorder (ASD), and other infections, including those caused by pathogens like Campylobacter and Shigella.

Unlike typical smaller biotechs, Immuron is generating revenue today. Its commercially-available Travelan, an over-the-counter product for treatment of Traveler’s Diarrhea, is generating steady sales growth, reaching $1.4M (AUS) in the most recent period, a 40% year-over-year increase.

Learn more about Immuron by reading our full report: https://www.redchip.com/assets/reports/IMRN_ResearchNote_20171023.html

 

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.

The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).

Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.

We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.

Immuron Ltd. (IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for 12 months of investor awareness services.

Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.




"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market